secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001867096-23-000106
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Founder and CSO Steven Prestrelski resigns, becomes Senior Scientific Advisor at Xeris Biopharma
--------------------------------------------------------------------------------

- Steven Prestrelski, PhD, Founder and Chief Scientific Officer, resigned effective June 30, 2023.
- He entered a consulting agreement as Senior Scientific Advisor from July 1, 2023 to January 31, 2025.
- The consulting agreement covers predefined services; no further financial terms disclosed.
- Transition follows founder's departure from executive role but retention as advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000106/0001867096-23-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000106/xers-20230628.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer